🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. Armodafinil 150 mg/day

    Teva Pharma GmbH

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  2. Armodafinil 150 mg/day

    Teva Pharma GmbH

    Excessive Sleepiness

    phase 3 small molecule completed

    1 trial

  3. Armodafinil 250 mg/day

    Teva Pharma GmbH

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  4. Armstrong Albuterol Sulfate Inhalation Aerosol

    Amphastar France Pharmaceuticals

    Asthma

    phase 3 small molecule terminated

    1 trial

  5. Aromatase Inhibitors

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    1 trial

  6. Arsenic trioxide

    Teva Pharma GmbH

    Acute Promyelocytic Leukemia

    phase 3 small molecule completed

    1 trial

  7. Arsenic trioxide

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  8. Asciminib

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 3 small molecule completed

    1 trial

  9. Asenapine Sublingual Tablets 10 mg

    Amneal Pharma Europe Ltd

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  10. Aspirin

    United Therapeutics Europe Ltd

    Node Positive HER2 Negative Breast Cancer

    phase 3 small molecule terminated

    1 trial

  11. Aspirin 75 mg daily

    Century Therapeutics

    Intracerebral Haemorrhage

    phase 3 small molecule active

    1 trial

  12. Aspirin® protect 100 mg Magensaftresistente Tablette Acetylsalicylsäure, Aspirin® protect 300 mg Magensaftresistente Tablette Acetylsalicylsäure, Placebo of Aspirine 100 mg protect, placebo of aspirin 300 mg protect

    Pari Pharma GmbH

    Colorectal adenomas, Lynch syndrome

    phase 3 small molecule active

    1 trial

  13. Astragalus Membranaceus

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Aneurysmal Subarachnoid Hemorrhage

    phase 3 small molecule active

    1 trial

  14. Asundexian (BAY2433334)

    Bayer HealthCare AG

    Prevention of Stroke or Systemic Embolism

    phase 3 small molecule terminated

    1 trial

  15. Asundexian (BAY2433334)

    Bayer HealthCare AG

    Prevention of Ischemic Stroke

    phase 3 small molecule completed

    1 trial

  16. Ataluren

    PTC THERAPEUTICS, INC.

    Cystic Fibrosis

    phase 3 small molecule completed

    6 trials

  17. Ataluren (PTC124®)

    PTC THERAPEUTICS, INC.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  18. Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ, 50 IU/ml, prášek a rozpouštědlo pro infuzní roztok, Atenativ 500 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 50 i.e./ml prašek in vehikel za raztopino za infundiranje, Atenativ 50 IU/ml prášek a rozpouštědlo pro infuzní roztok, ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, ATENATIV 50 UI/mL, poudre et solvant pour solution p

    Lacuna Pharma Pty Ltd

    Acquired Antithrombin Deficiency (Heparin Resistance)

    phase 3 small molecule active

    1 trial

  19. Atezolizumab

    Hoffmann-La Roche

    Melanoma

    phase 3 small molecule completed

    1 trial

  20. Atezolizumab

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  21. Atezolizumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 3 small molecule active

    1 trial

  22. Atezolizumab

    Jazz Pharmaceuticals Ireland Limited

    Small-Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  23. Atezolizumab

    Hoffmann-La Roche

    Urothelial Carcinoma

    phase 3 small molecule completed

    2 trials

  24. Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources